Yes, a woman receiving IV methylprednisolone can safely breastfeed her baby.
Based on the most recent 2025 EULAR guidelines and supporting pharmacokinetic data, glucocorticoids including intravenous methylprednisolone are compatible with breastfeeding, as they appear at very low concentrations in breast milk with minimal infant exposure 1, 2.
Evidence Supporting Safety
The 2025 EULAR recommendations explicitly state that glucocorticoids are compatible with breastfeeding, with new data specifically addressing IV methylprednisolone pulses (1000 mg) showing very low concentrations in breast milk 2. The maximum methylprednisolone levels occur 1-2 hours after administration 2.
Pharmacokinetic Data
High-quality pharmacokinetic studies demonstrate:
- Peak concentration in breast milk: 2.09 μg/mL at the end of infusion 3
- Relative infant dose (RID): 0.50-0.71% of the weight-adjusted maternal dose 3, 4
- Timing: Concentrations decline rapidly, becoming undetectable by 24 hours post-infusion 3, 4
The RID values are well below the generally accepted safety threshold of 10% for medication compatibility with breastfeeding.
Practical Recommendations
Women can breastfeed immediately after IV methylprednisolone administration without significant risk to the infant. However, if mothers wish to minimize infant exposure further:
- Wait 2-4 hours after infusion completion to substantially reduce the already-low methylprednisolone concentration in breast milk 3, 4
- Mothers may express and discard milk during this 2-4 hour window if desired, though this is not medically necessary given the low RID
Important Context
The 2025 EULAR guidelines emphasize a new overarching principle: "Given the benefits of breastfeeding, women should not be discouraged from breastfeeding while taking compatible medications" 1. This reflects the substantial benefits of breastfeeding for both infant (protection against infections, inflammatory bowel disease, obesity, diabetes, childhood cancers) and mother (reduced risks of diabetes, hypertension, breast, ovarian, endometrial and thyroid cancer) 1.
Common Pitfall to Avoid
Do not unnecessarily discourage breastfeeding or recommend prolonged "pump and dump" periods. The evidence clearly shows minimal transfer into breast milk and no reported adverse effects in breastfed infants whose mothers received IV methylprednisolone 3, 4. Historical concerns about glucocorticoid exposure during lactation are not supported by current pharmacokinetic data.
The risk of untreated maternal disease outweighs the minimal theoretical risk from methylprednisolone exposure through breast milk 1.